30th week of 2010 patent applcation highlights part 36 |
Patent application number | Title | Published |
20100189638 | COMPACT EXCHANGER-REACTOR USING A PLURALITY OF POROUS BURNERS - The present invention describes a novel exchanger-reactor intended to implement highly endothermic reactions such as natural gas or naphtha steam reforming, using in situ porous burners. | 2010-07-29 |
20100189639 | REFORMER, AND METHOD FOR REACTING FUEL AND OXIDANT TO GASEOUS REFORMATE - The invention relates to a reformer for reacting fuel and oxidant to a gaseous reformate, comprising an oxidation zone, an evaporation zone and a zone for catalytic H | 2010-07-29 |
20100189640 | METHOD FOR MAKING MOLECULAR SIEVE SSZ-79 - The present invention is directed to a method for making new crystalline molecular sieve designated SSZ-79 using 1,8-dimethyl-1,4,8,11-tetraazacyclotetradecane or 1,4,8,11-tetramethyl-1,4,8,11-tetraazacyclotetradecane as a structure directing agent. | 2010-07-29 |
20100189641 | Novel Strategies for Improved Cancer Vaccines - The present invention concerns methods and compositions for forming anti-cancer vaccine complexes. In preferred embodiments, the anti-cancer vaccine complex comprises an antibody moiety that binds to dendritic cells, such as an anti-CD74 antibody or antigen-binding fragment thereof, attached to an AD (anchoring domain) moiety and a xenoantigen, such as CD20, attached to a DDD (dimerization and docking domain) moiety, wherein two copies of the DDD moiety form a dimer that binds to the AD moiety, resulting in the formation of the vaccine complex. The anti-cancer vaccine complex is capable of inducing an immune response against xenoantigen expressing cancer cells, such as CD138 | 2010-07-29 |
20100189642 | RADIONUCLIDES FOR MEDICAL USE - Methods of using Th-226 or mother radionuclides thereof, namely U-230 or Th-226, in medicine. These radionuclides are particularly appropriate for the treatment of human and/or non-human mammals, in particular for therapeutic, diagnostic (detection/imaging), prophylactic and pain palliation purposes. These radionuclides may be used in various forms for treatment and/or diagnostic purposes, in particular in cationic form or in the form of radioconjugates or bone-targeting complexes. Methods of making such radionuclides. | 2010-07-29 |
20100189643 | DRUG DELIVERY WITH STIMULUS RESPONSIVE BIOPOLYMERS - The present invention provides conjugate compounds comprising (a) an active compound; (b) optionally, but in some embodiments preferably, an affinity binding agent; and (c) a block copolymer, the block copolymer comprising: (i) a first elastin-like polypeptide having a first Tt and (U) a second elastin-like polypeptide having a second Tt greater than the first Tt. Method for the targeted delivering of an active compound in vivo to a selected region within a subject with such agents are also described. | 2010-07-29 |
20100189644 | ARGINASE INHIBITORS AND METHODS OF USE - The present invention is directed to arginase inhibitor compounds of formula IA or formula IB: | 2010-07-29 |
20100189645 | METAL CHELATORS AND METHODS OF THEIR USE - Metal chelators of Formula I and Formula II are disclosed: | 2010-07-29 |
20100189646 | Carbazole Derivatives as Functional 5-HT6 Ligands - The present invention provides carbazole derivatives of formula (I), useful in treatment of a CNS disorders related to or affected by the 5-HT | 2010-07-29 |
20100189647 | Experimental Animal As Pathological Model, Method of Producing the Experimental Animal, and Method of Using the Experimental Animal - Problem to be Solved: There are provided a novel pathological model with an experimental animal which reproduces human nonalcoholic chronic hepatitis and/or liver fibrosis and/or cirrhosis progressed from fatty liver, a method for producing the same, and a method for utilizing the novel pathological model with an experimental animal. | 2010-07-29 |
20100189648 | INHIBITORS FOR DISRUPTING THE INTERACTION OF UBIQUITINATION RELATED ENZYMES AND USES THEREOF - A hydrophobic binding pocket on ubiquitin-protein ligase E3 is described, and used in designing the inhibitors disrupting ubiquitin conjugating enzyme E2 and E3 interaction. Four types of inhibitors designed by using the binding pocket are provided, which can be used for cancer treatment. | 2010-07-29 |
20100189649 | MONOCLONAL ANTIBODIES TO ACTIVATED ERBB FAMILY MEMBERS AND METHODS OF USE - Antibodies which bind to activated members of the erbB, TNF, and IgSF family of receptors and pharmaceutical compositions comprising the same are disclosed. Peptides and mimetics of erbB, TNF, and IgSF receptors and pharmaceutical compositions comprising the same are also described. Methods of using such antibodies, peptides, and mimetics in tumor therapeutic, prophylactic, imaging and diagnostic applications are disclosed. | 2010-07-29 |
20100189650 | Near-Infrared Responsive Carbon Nanostructures - The present invention provides for compositions comprising carbon nanotubes (CNT) and gold (Au). The present invention further provides methods of manufacture of gold-carbon nanotubes (gCNT). The present invention provides methods of using gCNT for biological application. | 2010-07-29 |
20100189651 | MODIFIED ANTIBODY COMPOSITIONS, METHODS OF MAKING AND USING THEREOF - The present disclosure provides modified antibodies which contain an antibody or antibody fragment (AB) modified with a masking moiety (MM). Such modified antibodies can be further coupled to a cleavable moiety (CM), resulting in activatable antibodies (AAs), wherein the CM is capable of being cleaved, reduced, photolysed, or otherwise modified. AAs can exhibit an activatable conformation such that the AB is more accessible to a target after, for example, removal of the MM by cleavage, reduction, or photolysis of the CM in the presence of an agent capable of cleaving, reducing, or photolysing the CM. The disclosure further provides methods of making and using such modified antibodies and activatable antibodies. | 2010-07-29 |
20100189652 | NOVEL DIAGNOSTIC MARKERS, ESPECIALLY FOR IN VIVO IMAGING, AND ASSAYS AND METHODS OF USE THEREOF - Novel splice variants as diagnostic markers, preferably membrane-bound. The novel variants according to the present invention may optionally be used for diagnosis of Marker-detectable disease as described herein, optionally through immunohistochemistry. | 2010-07-29 |
20100189653 | Pyrone analogs for therapeutic treatment - Methods are described for the treatment and prevention of metabolic disorders or other diseases by administering a pyrone analog or a derivative thereof. Methods are also described for the treatment and prevention of metabolic disorders and other diseases by administering a pyrone analog, or a derivative thereof, in combination with one or more additional agents such as, for example, lipid lowering agents or glucose lowering agents. Methods are described for the modulation of lipid transporter activity to increase the efflux of lipid from a physiological compartment into an external environment. Methods disclosed herein may be used to assess treatment or prevention of a metabolic disorder following administration of a pyrone analog or a derivative thereof. | 2010-07-29 |
20100189654 | ANIMAL MODEL FOR EVALUATING VASOMOTOR RESPONSE IN VIVO - A method for evaluating the effect of a compound on vasomotor response in vivo comprises the steps of administering said compound to a rabbit and measuring the diameter of the vessel lumen of a central ear artery of said rabbit in comparison with the baseline diameter of the vessel lumen of said central ear artery of said rabbit, said baseline diameter being measured prior to the administration of said compound. | 2010-07-29 |
20100189655 | METHODS FOR TREATING HEADACHE - A headache can be treated more effectively by co-administration of a botulinum toxin and a triptan drug to a patient and/or the effectiveness of a triptan medication can be increased. The botulinum toxin can be botulinum toxin type A and the botulinum toxin can be administered to or to the vicinity of where a patient experiences or is predisposed to experience pain or a headache. | 2010-07-29 |
20100189656 | CONTRAST AGENTS - The present invention relates to a class of compounds and to diagnostic compositions containing such compounds where the compounds are iodine containing compounds. More specifically the iodine containing compounds are chemical compounds containing a triamine alkyl central moiety allowing for the arrangement of three iodinated phenyl groups bound thereto. The invention also relates to the use of such diagnostic compositions as contrast agents in diagnostic imaging and in particular in X-ray imaging and to contrast media containing such compounds. | 2010-07-29 |
20100189657 | INTRAMOLECULARLY QUENCHED FLUOROCHROME CONJUGATES AND METHODS OF USE - The invention provides a quenched fluorochrome conjugate and methods of use thereof in the detection and treatment of disorders characterized by unwanted cellular proliferation including cancer. | 2010-07-29 |
20100189658 | Imaging probes - The present invention relates to molecular probes of the formula (I) | 2010-07-29 |
20100189659 | DIAGNOSTIC SUBSTANCE AND METHOD FOR THE DIAGNOSIS OF PROSTATE DISEASES - A diagnostic substance for use in a method for diagnosing prostate diseases contains multiple different coupling molecules that respectively bind to signal molecules (target molecules) of a molecular surface structure of a pathological tissue that is associated with a prostate disease. A first of the coupling molecules specifically binds to signal molecules of cancer tissue, and a second of the coupling molecules specifically binds to signal molecules formed in inflamed tissue. First and second markers are respectively associated with the first and second coupling molecules, the first and second markers being detectable, and differentiated from each other, with a detection device. | 2010-07-29 |
20100189660 | METHODS FOR THE DETECTION OF FATTY-ACYLATED PROTEIN - Sensitive, non-radioactive fatty-acyls of Formula I are useful in in vivo methods for detection and cellular imaging of a fatty-acylated substrate (e.g., protein or polypeptide). | 2010-07-29 |
20100189661 | POLYMER-BOUND UV ABSORBERS IN PERSONAL CARE COMPOSITIONS - Personal care compositions comprising a polymer-bound UV absorber are described that provide enhanced properties, including customizable UV spectrum protection, broad-spectrum UV spectrum protection, water resistance, and labile UV stabilization. The polymer comprises anhydride functionality, such as maleic anhydride or a derivative thereof, and the UV absorber contains at least one hydroxyl, primary amine, or secondary amine group. | 2010-07-29 |
20100189662 | DMS (derma membrane structure) in Foam Creams - The invention relates to a foam formulation comprising an emulsion, comprising an oil phase and a water phase, the oil phase comprising at least one membrane-forming substance forming a lamellar membrane in the foam formulation. | 2010-07-29 |
20100189663 | MOUTH RINSE COMPOSITIONS INCLUDING CHEMICALLY MODIFIED SILICA OR SILICATE MATERIALS FOR SUSTAINED DELIVERY TO TOOTH SURFACES - Novel mouth rinse (i.e., mouthwash) compositions that permit delivery of silica or silicate materials to the surface of teeth through common mouth rinsing procedures are provided. Such compositions must exhibit proper suspension of the silica or silicate materials (in particulate form) to prevent settling during storage while simultaneously providing proper mouth rinsing properties. Such silica or silicate materials may themselves exhibit any number of therapeutic or aesthetic benefits as long as such materials are easily transferred through mouth rinsing and exhibit proper affinity for deposit on target teeth upon contact therewith. Such silica or silicate materials should exhibit, in one embodiment, certain ionic charge levels as well as sufficiently small particle sizes to permit effective static attraction and eventual accumulation on target tooth surfaces. Methods of utilizing such mouthwashes for breath freshening and/or cleaning, as well as silica or silicate material tooth accumulation, are encompassed within this invention as well. | 2010-07-29 |
20100189664 | COSMETIC AGENTS BASED ON VINYLIMIDAZOLE POLYMERS - The present invention relates to aqueous or aqueous-alcoholic compositions comprising at least one cationic polymer a) and at least one polymer b) with a molecular weight M | 2010-07-29 |
20100189665 | Cosmetic Preparations Containing Hydrocarbons - The invention relates to cosmetic and/or pharmaceutical preparations that contain selected hydrocarbons. | 2010-07-29 |
20100189666 | Cocoon-Shaped Rutile-Type Titanium Dioxide, As Well As Cosmetics And External Additives For Toner Comprising the Same - The present invention provides products comprising rutile-type titanium dioxide of a specific shape, i.e., cosmetics which have high UV blocking ability, provide a good feel upon use without leaving squeakiness or graininess on the skin, and also give a natural bare skin appearance without causing white masking, due to adequate tinting strength and covering power, as well as external additives for toner which are excellent in prevention of filming on a photosensitive member and inhibition of aggregation between toner particles. | 2010-07-29 |
20100189667 | VESICLES OF HIGH MOLECULAR WEIGHT SILICONE POLYETHERS - Vesicle compositions from high molecular weight silicone polyether copolymers, methods for preparing the vesicle compositions, and personal, household, and healthcare formulations containing the vesicle compositions are disclosed. | 2010-07-29 |
20100189668 | Composition for treating herpes simplex viral infections, the method, use and process by which the composition is utilized and the manufacture of the composition - This invention relates to a composition, method and process for the treatment of the herpes simplex virus which causes cold sores in humans by a topical application of a blend of essential oils and other natural based materials as a dilutant, all of which may be delivered in either a solid, paste, powder, gel or liquid form to the affected area. | 2010-07-29 |
20100189669 | Regulation of Mammalian Keratinous Tissue Using Skin and/or Hair Care Actives - Personal care compositions containing an active selected from the group consisting of phlorogine, phlorgine BG, deoxyArbutin, sucrose dilaurate, bakuchiol, pyrenoine, millet, arlatone dioic acid, cinnamic acid, ferulic acid, achromaxyl, methyl nicotinamide, oil soluble licorice extract, folic acid, undecylenic acid, zinc undecylenate, L-tryptophan, thiamine HCl, hexylresorcinol, lipidami red vine, dragosine, methyl gentisate, inositol, symdiol 68, laminaine, their salts, their derivatives, their precursors, and/or combinations thereof. Methods for regulating the condition of mammalian keratinous tissue by topically applying the personal care compositions are also provided. | 2010-07-29 |
20100189670 | METHOD FOR ENHANCING EFFECTS OF COLORANTS AND CONDITIONERS - Methods are provided for enhancing the longevity of the binding of various benefit agents to hair and skin. Applications of traditional and non-traditional colorants and conditioners to hair and skin are amended with compositions of hair or skin-binding peptides respectively. The presence of the hair or skin-binding peptide compositions act to increase the longevity of the applied colorant or conditioner on the hair or skin. | 2010-07-29 |
20100189671 | INDOLE AMIDES AS PERFUMING INGREDIENTS - The present invention concerns the use of some indole amide derivatives as perfuming ingredients. | 2010-07-29 |
20100189672 | DECALINE DERIVATIVES AS PERFUMING INGREDIENTS - The present invention relates to a new class of compounds, α-decalones or decalols with a 6,7,8a-trimethyl substitution, and their use in perfumery to confer odor notes of the citrus (e.g. grapefruit) type. | 2010-07-29 |
20100189673 | Hydrocarbon Mixtures and Use Thereof - The invention relates to hydrocarbon mixtures containing the | 2010-07-29 |
20100189674 | Petrolatum Having Silicone-Like Properties - Novel petrolatums having silicone-like properties are disclosed. Silicone-free compositions containing the novel petrolatums also are disclosed. | 2010-07-29 |
20100189675 | COSMETIC USE OF AN IMIDOPERCARBOXYLIC ACID DERIVATIVE AS DESQUAMATING AGENT - The present invention relates to the cosmetic use of at least one imidopercarboxylic acid derivative in a cosmetic composition comprising a physiologically acceptable medium, as agent for promoting desquamation of the skin and/or the scalp and/or for stimulating epidermal renewal, the associated method of cosmetic treatment and a composition comprising the said imidopercarboxylic acid derivative and a desquamating agent and/or an anti-ageing agent. | 2010-07-29 |
20100189676 | COSMETIC PREPARATION COMPRISING SILICONE - The present invention discloses a cosmetic preparation which comprises 20 mass % or more of an oil ingredient comprising the following components (A) and (B), and said oil ingredient comprising 50 mass % or more of the component (B):
| 2010-07-29 |
20100189677 | GEL CONCENTRATED IN BRANCHED SULFONIC POLYESTER AND METHOD FOR PREPARING SAME - A cosmetic composition in the form of a gel with a high concentration of branched sulphonic polyester and a method for preparing said gel and using same for producing cosmetic compositions in any galenic form. | 2010-07-29 |
20100189678 | Hair Preparation Containing Two Copolymers - Cosmetics, particularly styling agents, containing at least one copolymer A composed of at least one monomer A1 chosen from acrylic acid, methacrylic acid, alkyl acrylates, and alkyl methacrylates, and at least one amphoteric monomer A2 chosen from (meth)acryloyl alkyl betaines and (meth)acryloyl alkyl amine oxides, and at least one film-forming and/or stabilizing anionic copolymer B in a cosmetically acceptable carrier. Also disclosed is the use of said cosmetics for temporarily shaping hair. | 2010-07-29 |
20100189679 | CROSSLINKED POLYALLYLAMINE OR ACID ADDITION SALT THEREOF, AND USE THEREOF FOR MEDICAL PURPOSES - A cross-linked polyallylamine or an acid addition salt thereof has both high phosphate adsorption capability and low degree of swelling, and a medical use thereof. The cross-linked polyallylamine or an acid addition salt thereof is obtained by copolymerization of allylammonium dihydrogen phosphate with an acid addition salt of N,N′-diallyl-1,3-diaminopropane in an amount of 5 to 25 mol % with respect to the amount of the allylammonium dihydrogen phosphate, the cross-linked polyallylamine or an acid addition salt thereof having a phosphate adsorption capacity of 2.7 to 5.0 mmol/g; and a degree of swelling of 2.0 to 5.0. The cross-linked polyallylamine or an acid addition salt thereof is useful as a therapeutic or prophylactic agent for hyperphosphatemia. | 2010-07-29 |
20100189680 | Methods of Treating Various Cancers Using Melanoma Differentiating Associated Protein-7 - This invention provides a method for reversing the cancerous phenotype of a cancer cell by introducing a nucleic acid having the melanoma differentiation associated gene (mda-7) into the cell under conditions that permit the expression of the gene so as to thereby reverse the cancerous phenotype of the cell. This invention also provides a method for reversing the cancerous phenotype of a cancer cell by introducing the gene product of the above-described gene into the cancerous cell so as to thereby reverse the cancerous phenotype of the cell. This invention also provides a pharmaceutical composition having the melanoma differentiation associated gene (mda-7) or the gene product of the melanoma differentiation associated gene (mda-7) effective to reverse the cancerous phenotype of a cancer cell and a pharmaceutically acceptable carrier. | 2010-07-29 |
20100189681 | Methods of Using Phosphoantigens Together with Interleukin-2 for the Treatment of Cancer - The present invention therefore provides novel approaches and strategies for efficient regulation of γδ T cells in vivo, in a subject, particularly a human subject or a non-human primate. The present invention now discloses particular compositions and methods that can be used to induce the proliferation of γδ T cells in vivo, in a subject. These compositions and methods employ the conjoint treatment of an individual with a γδ T cell activating compound and IL-2 and are particularly suited for immunotherapy in a subject, particularly in a subject having a cancer or an infectious disease. | 2010-07-29 |
20100189682 | Biologically active proteins having increased In Vivo and/or In Vitro stability - The present invention provides unstructured recombinant polymers (URPs) and proteins containing one or more of the URPs. The present invention also provides microproteins, toxins and other related proteinaceous entities, as well as genetic packages displaying these entities. The present invention also provides recombinant polypeptides including vectors encoding the subject proteinaceous entities, as well as host cells comprising the vectors. The subject compositions have a variety of utilities including a range of pharmaceutical applications. | 2010-07-29 |
20100189683 | Pulsatile Dosing of Gossypol for Treatment of Disease - This invention relates to pulsatile dose administration of gossypol or pharmaceutical compositions thereof for treating diseases, disorders and conditions responsive to gossypol, inhibiting the activity of anti-apoptotic Bcl-2 family proteins, inducing apoptosis in cells and increasing the sensitivity of cells to inducers of apoptosis. | 2010-07-29 |
20100189684 | USE OF gp130 ACTIVATORS IN DIABETIC NEUROPATHY - The invention relates to the use a substance signaling through gp130 for the manufacture of a medicament for the treatment and/or prevention of diabetic neuropathy. The use of IL-6 is preferred. | 2010-07-29 |
20100189685 | Antiviral Drugs for Treatment or Prevention of Dengue Infection - Compounds, methods and pharmaceutical compositions for treating viral infections, by administering certain compounds in therapeutically effective amounts are disclosed. Methods for preparing the compounds and methods of using the compounds and pharmaceutical compositions thereof are also disclosed. In particular, the treatment and prophylaxis of viral infections such as caused by flavivirus is disclosed, i.e., including but not limited to, Dengue virus, West Nile virus, yellow fever virus, Japanese encephalitis virus, and tick-borne encephalitis virus. | 2010-07-29 |
20100189686 | Albumin Fusion Proteins - The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention. | 2010-07-29 |
20100189687 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS - The present application provides for a compound of Formula IV, or a pharmaceutically acceptable salt, solvate, and/or ester thereof, compositions containing such compounds, therapeutic methods that include the administration of such compounds, and therapeutic methods and include the administration of such compounds with at least one additional therapeutic agent. | 2010-07-29 |
20100189688 | Dose forms comprising VX-950 and their dosage regimen - The present invention relates to antiviral therapies and compositions for treating or preventing Hepatitis C infections in patients and relates to other methods disclosed herein. The invention also relates to kits and pharmaceutical packs comprising compositions and dosage forms. The invention also relates to processes for preparing these compositions, dosages, kits, and packs. | 2010-07-29 |
20100189689 | Tetrameric Cytokines with Improved Biological Activity - The present invention concerns methods and compositions for forming cytokine-antibody complexes using dock-and-lock technology. In preferred embodiments, the cytokine-MAb DNL complex comprises an IgG antibody attached to two AD (anchor domain) moieties and four cytokines, each attached to a DDD (docking and dimerization domain) moiety. The DDD moieties form dimers that bind to the AD moieties, resulting in a 2:1 ratio of DDD to AD. The cytokine-MAb complex exhibits improved pharmacokinetics, with a significantly longer serum half-life than either naked cytokine or PEGylated cytokine. The cytokine-MAb complex also exhibits significantly improved in vitro and in vivo efficacy compared to cytokine alone, antibody alone, unconjugated cytokine plus antibody or cytokine-MAb DNL complexes incorporating an irrelevant antibody. In more preferred embodiment the cytokine is G-CSF, erythropoietin or INF-α2b. | 2010-07-29 |
20100189690 | PSEUDOTYPING OF RETROVIRAL VECTORS, METHODS FOR PRODUCTION AND USE THEREOF FOR TARGETED GENE TRANSFER AND HIGH THROUGHPUT SCREENING - The invention relates to the pseudotyping of retroviral vectors with heterologous envelope proteins derived from the Paramyxoviridae family, genus | 2010-07-29 |
20100189691 | E. Coli Mediated Gene Silencing of Beta-Catenin - Methods are described for the delivery of one or more small interfering RNAs (siRNAs) to a eukaryotic cell using a bacterium or BTP. Methods are also described for using this bacterium to regulate gene expression in eukaryotic cells using RNA interference, and methods for treating viral diseases and disorders. The bacterium or BTP includes one or more siRNAs or one or more DNA molecules encoding one or more siRNAs. Vectors are also described for use with the bacteria of the invention for causing RNA interference in eukaryotic cells. | 2010-07-29 |
20100189692 | PROBIOTICS FOR USE IN REDUCING EOSINOPHILIA AND RESPIRATORY ALLERGIES - The present invention provides probiotic compositions suitable for reducing the incidence and duration of nasal eosinophilia and other parameters associated with birch pollen allergy. In some embodiments, the present invention provides methods and/or compositions suitable for reducing nasal and/or respiratory allergy symptoms. | 2010-07-29 |
20100189693 | Novel Pasteuria Strain - The subject invention provides a novel and advantageous strain of | 2010-07-29 |
20100189694 | Scar Tissue Treatment System - A treatment for hypertrophic scar tissue and methods for treatment of hypertrophic scar tissues utilizing viable fibroblast cells. | 2010-07-29 |
20100189695 | IRAK-1 AS REGULATOR OF DISEASES AND DISORDERS - The present invention provides methods and compositions for treatment of diseases and disorders. More specifically, the invention for the first time shows a link between IRAK-1 and phosphorylation of proteins involved in cardiovascular disease, diabetes, neurodegeneration, and associated diseases and disorders and complications. Typically, the diseases and disorders involve an inflammatory component. Assays for bioactive substances affecting IRAK-1 regulated progression of inflammation and diseases and disorders involving inflammation are also disclosed. | 2010-07-29 |
20100189696 | LITHIUM STIMULATION OF CORD BLOOD STEM CELL PROLIFERATION AND GROWTH FACTOR PRODUCTION - The present invention provides methods for expanding human umbilical cord blood stem cells and methods for stimulating growth factor production by cord blood stem cells using an in vitro cell culture system comprising a lithium salt. The present invention also provides in vivo methods for enhancing the survival and growth of transplanted cord blood stem cells by treating the cells with a lithium salt prior to transplantation. In vivo methods for reducing rejection of transplanted cord blood stem cells by administering a lithium salt after transplantation are also provided. | 2010-07-29 |
20100189697 | CARDIAC-SPECIFIC PROGENITOR CELLS - This document provides methods and materials related to treating cardiovascular tissue (e.g., heart tissue or vascular tissue). For example, stem cells (e.g., CXCR4+/Flk-1+ stem cells), compositions containing stem cells, methods for obtaining stem cells, and methods for repairing cardiovascular tissue are provided. | 2010-07-29 |
20100189698 | TREATMENT OR PROPHYLAXIS OF A NEUROLOGICAL OR NEUROPSYCHIATRIC DISORDERS VIA OCULAR ADMINISTRATION - A method for the treatment and/or prophylaxis of a neurological and/or neuropsychiatric disorder associated with altered dopamine function comprising administering to the eye of a patient in need thereof an effective amount of an agent that modulates neurotransmitter production or function. | 2010-07-29 |
20100189699 | METHOD OF CONSTRUCTING MASSES OF MYOCARDIAL CELLS AND USE OF THE MYOCARDIAL CELL MASS - The object of the present invention is to improve the post-transplantation engraftment rate of cardiomyocytes that have been purified to such an extent that they are free from non-cardiomyocytes and any components derived from other species. | 2010-07-29 |
20100189700 | CULTURE FOR EXPANDING STEM CELLS EX-VIVO - The present invention relates to a culture including a growth medium and a combination of cytokines consisting of i) interleukin-6 (IL6); ii) flt3-ligand (FLT3); iii) stem cell factor (SCF) and iv) thrombopoi-etin (TPO); the use of the culture for expanding. ex vivo stem cells and/or parental cells and cells differentiated therefrom, and the use of said cells obtainable from said expansion. | 2010-07-29 |
20100189701 | METHODS AND COMPOSITIONS TO TREAT ARRHYTHMIAS - The present invention provides compositions and methods of treatment for atrial fibrillation and ventricular tachycardia. The compositions are useful for modifying the conducting properties of heart tissues in which impulses are generating and/or are useful for altering refractoriness without prolonging repolarization. | 2010-07-29 |
20100189702 | COMPOSITIONS AND METHODS FOR RESTORING BACTERIAL FLORA - The invention provides compositions, kits, and methods for providing or restoring beneficial bacteria to a subject. The compositions and kits optionally include food or nutrients to promote growth and proliferation of the bacteria in the subject or an antimicrobial agent to reduce the presence of undesirable or pathogenic microbes in the subject. | 2010-07-29 |
20100189703 | NON-DESTRUCTIVE METHOD TO QUANTIFY AND ISOLATE ANTIGEN-SPECIFIC B CELLS AND USES THEREOF - The present invention relates to antigen-Ig Ab fusion molecules and methods of using same, wherein antigen-Ig Ab fusion molecules include an antigen fused to an immunoglobulin molecule, fragment or variant thereof and wherein the fusing of the immunoglobulin molecule to the antigen does not alter the specificity or tertiary structure of important epitopes of the antigen. This method allows the direct quantification and isolation of antigen-specific B cells by flow cytometry in essentially any species. | 2010-07-29 |
20100189704 | Dietary supplement enhancing the muscular energy metabolism, comprising an alkanoyl carnitine and ribose - A method for treating myocardial or skeletal muscle anoxia which occurs in coronary or post-infarct disorders or during prolonged physical activity and muscle fatigue. This method comprises the administration of a combination composition comprising (a) an alkanoyl L-carnitine selected from the group consisting of isovaleryl L-carnitine, propionyl L-carnitine or the pharmacologically acceptable salts thereof or mixtures thereof; and (b) ribose or a phosphate derivative thereof | 2010-07-29 |
20100189705 | BIOLOGICAL DECONTAMINATION SYSTEM - A composition for decontaminating biological pathogens and a system and method for mixing and applying the composition to contaminated sites are presented. The composition of the invention is suitable for the decontamination of biological warfare agents, including | 2010-07-29 |
20100189706 | ENZYMES FOR THE TREATMENT OF LIGNOCELLULOSICS, NUCLEIC ACIDS ENCODING THEM AND METHODS FOR MAKING AND USING THEM - The invention provides polypeptides having a lignocellulolytic activity, e.g., a glycosyl hydrolase, a cellulase, an endoglucanase, a cellobiohydrolase, a beta-glucosidase, a xylanase, a mannanse, a xylosidase (e.g., a β-xylosidase), an arabinofuranosidase, and/or a glucose oxidase activity, polynucleotides encoding these polypeptides, and methods of making and using these polynucleotides and polypeptides. In one aspect, the invention provides polypeptides that can enzymatically process (hydrolyze) sugarcane bagasse, i.e., for sugarcane bagasse degradation, or for biomass processing, and polynucleotides encoding these enzymes, and making and using these polynucleotides and polypeptides. In one embodiment, the invention provides thermostable and thermotolerant forms of polypeptides of the invention. The polypeptides of the invention can be used in a variety of pharmaceutical, agricultural and industrial contexts; for example, the invention provides a multi-enzyme system that can hydrolyze polysaccharides in a bagasse component of sugarcane processed in sugar mills. The invention provides enzymes for the bioconversion of lignocellulosic residues into fermentable sugars; and these sugars can be used as a chemical feedstock for the production of ethanol and fuels, including biofuels such as bioethanol, biopropanol, biobutanol and biodiesels. | 2010-07-29 |
20100189707 | Stable Enzymatic Peracid Generating Systems - The present invention provides stable compositions comprising a perhydrolase enzyme, a hydrogen peroxide source, and an ester substrate that efficiently generate aqueous peracid solutions. The generated peracid solutions are suitable for decontaminating and/or sanitizing a wide range of materials and equipment contaminated with pathogens or toxic chemicals. In one preferred embodiment, the stable composition comprises an acyl transferase enzyme, sodium percarbonate, and propylene glycol diacetate, and is stable for 30 days or longer. Upon addition to water, the composition is activated and generates an aqueous solution with a high ratio of peracetic acid to acetic acid. | 2010-07-29 |
20100189708 | HYDROXY PIPERIDINE DERIVATIVES TO TREAT GAUCHER DISEASE - The present invention provides novel hydroxy piperidine (HP) derivatives having (i) a positive charge at the position corresponding to the anomeric position of a pyranose ring; (ii) a short, flexible linker emanating from the corresponding position of the ring oxygen in a pyranose; and (iii) a lipophilic moiety connected to the linker and pharmaceutically acceptable salts thereof. The linker can be absent if the lipophilic moiety corresponds to a hydrocarbon chain with a linear length of 6 or more carbons. The present invention further provides a method for treating individuals having Gaucher disease by administering the novel HP derivative as “active-site specific chaperones” for the mutant glucocerebrosidase associated with the disease. | 2010-07-29 |
20100189709 | ELASTASE INHIBITOR - An elastase inhibitor containing, as an active ingredient, a protein hydrolysate (with soybean protein hydrolysate and almond protein hydrolysate being excluded). Pharmaceuticals and cosmetics containing such an elastase inhibitor which exhibit an inhibitory effect against the growth of body hair, and skin aging preventing effect by restoring elasticity and tonicity of the skin and reducing wrinkles. | 2010-07-29 |
20100189710 | MATERIAL FOR FACILITATING THERMAL TREATMENTS OF BIOLOGICAL TISSUES AND METHOD OF ENERGY TARGETING LEADING TO THERMAL TREATMENT OF BIOLOGICAL TISSUES - A method includes positioning an effective amount of a thermal target material at a treatment site of a patient. The treatment site, that is, the location of the thermal target material, comprises a location adjacent to biological tissue to be treated. The thermal target material includes carbon molecules preferably in a carrier fluid. Regardless of the particular structure of the carbon, the carbon molecules in the material heat very rapidly in response to incident microwave radiation and radiate heat energy. The heat energy radiated from an effective amount of the thermal target material when subjected to an effective quantity of microwave energy causes localized heating around the thermal target material. This localized heating may be applied for therapeutic purposes. However, the microwave radiation necessary to produce therapeutically effective heating is insufficient to cause cellular damage in the biological tissue by direct absorption in the tissue. | 2010-07-29 |
20100189711 | TUMOR IMMUNITY - Disclosed herein are materials and methods for treating cancer. In particular, compositions for stimulating tumor immunity through modulation of MFG-E8 are provided. | 2010-07-29 |
20100189712 | Preparation And Use Of Cell-Synthesized Threads - The present technology provides for a cell-synthesized biological thread, processes for making a cell-synthesized thread, and an apparatus for carrying out a process used to engineer the cell-synthesized thread. The thread is produced from living cells in culture and can be grown around the outer surface of a cylindrical bioreactor. The tissue comprising the thread has mechanical and biological properties achieved by altering the climactic conditions, stresses and strains on the tissue and chemical composition that prove beneficial in the medical industry. This process results in a biological thread that has high mechanical strength, decreased immunogenic effect and decreased thrombogenic effect when combined with other tissue. It also results in a product which can be used to create more complex constructs that otherwise could not have been generated. The threads can be used to make sutures, patches, and tubes, for example. | 2010-07-29 |
20100189713 | Use of Semaphorin 6A for Promoting Myelination and Oligodendrocyte Differentiation - The invention provides methods of treating diseases, disorsers or injuries involving demyelination and dysmyelination, including multiple sclerosis, by the administration of a Sema6A polypeptide. | 2010-07-29 |
20100189714 | POLYPEPTIDES WITH ENHANCED ANTI-INFLAMMATORY AND DECREASED CYTOTOXIC PROPERTIES AND RELATING METHODS - The invention provides a polypeptide containing at least one IgG Fc region, wherein said at least one IgG Fc region is glycosylated with at least one galactose moiety connected to a respective terminal sialic acid moiety by a α 2, 6 linkage, and wherein said polypeptide having a higher anti-inflammatory activity as compared to an unpurified antibody. | 2010-07-29 |
20100189715 | HUMANIZED MONOCLONAL ANTIBODIES THAT PROTECT AGAINST SHIGA TOXIN INDUCED DISEASE - The present invention describes the preparation and use of biologically and immunologically active humanized monoclonal antibodies to Shiga toxin, a toxin associated with HC and the potentially life-threatening sequela HUS transmitted by strains of pathogenic bacteria. The present invention describes how these humanized antibodies may be used in the treatment or prevention of Shiga toxin induced diseases. One aspect of the invention is the humanized monoclonal antibody which binds Shiga toxin where the constant regions are IgG1-kappa and the variable regions are murine in origin. Yet another aspect of the invention is expression vectors and host cells transformed with such vectors which express the humanized monoclonal antibodies of the present invention. | 2010-07-29 |
20100189716 | TREATMENT OF HODGKINS LYMPHOMA - Compositions comprising CD80 antagonists and methods using these compositions are provided for the treatment of Hodgkins lymphoma. More particularly, the disclosed CD80 antagonists may be used to induce apoptosis or lysis of Hodgkins Reed-Sternberg (HRS) cells, or to inhibit HRS cell activities that promote tumor development or progression. | 2010-07-29 |
20100189717 | Plant Recombinant Human CTLA4IG and a Method for Producing the Same - The present invention provides a recombinant vector pBI-3D-hGalT or pBI-35S-hGalT containing a human β1,4-galactosyltransferase gene; a cell line transformed with a recombinant vector pMYN414 containing a cytotoxic T-lymphocyte anti-gen A-immunoglobulin (CTLA4Ig) fusion protein gene and the recombinant vector pBI-3D-hGalT or pBI-355-hGalT; and a method for producing a plant-derived recombinant human CTLA4Ig (CTLA4Igp) fusion protein with a human glycan structure using the same. The plant cell-derived recombinant human CTLA4Ig fusion protein (CTLA4Igp), which has a human glycan structure and is produced according to the present invention, exhibits an improved in vivo half life as compared to conventional plant-derived proteins, due to the presence of a human-like glycan structure. Consequently, the present invention using the plant expression system enables low-cost mass production of a CTLA4Igp fusion protein having an immunosuppressive activity comparable to that of the CTLA4IgM fusion protein expressed in conventional animal cell expression systems. | 2010-07-29 |
20100189718 | MOLECULES WITH EXTENDED HALF-LIVES, COMPOSITIONS AND USES THEREOF - The present invention provides molecules, including IgGs, non-IgG immunoglobulins, proteins and non-protein agents, that have increased in vivo half-lives due to the presence of an IgG constant domain, or a portion thereof that binds the FcRn, having one or more amino acid modifications that increase the affinity of the constant domain or fragment for FcRn. Such proteins and molecules with increased half-lives have the advantage that smaller amounts and or less frequent dosing is required in the therapeutic, prophylactic or diagnostic use of such molecules. | 2010-07-29 |
20100189719 | ANTI-VEGF ANTIBODIES - Anti-VEGF antibodies and variants thereof, including those having high affinity for binding to VEGF, are disclosed. Also provided are methods of using phage display technology with naïve libraries to generate and select the anti-VEGF antibodies with desired binding and other biological activities. Further contemplated are uses of the antibodies in research, diagnostic and therapeutic applications. | 2010-07-29 |
20100189720 | NOVEL CARD PROTEINS INVOLVED IN CELL DEATH REGULATION - The present invention provides NB-ARC and CARD-containing proteins (NACs), nucleic acid molecules encoding NACs and antibodies specific for at least one NAC. The invention further provides chimeric NAC proteins. The invention also provides screening assays for identifying an agent that can effectively alter the association of a NAC with a NAC-associated protein. The invention further provides methods of modulating apoptosis in a cell by introducing into the cell a nucleic acid molecule encoding a NAC or an antisense nucleotide sequence. The invention also provides a method of using a reagent that can specifically bind to a NAC to diagnose a pathology that is characterized by an increased or decreased level of apoptosis in a cell. | 2010-07-29 |
20100189721 | ANTIBODY FORMULATIONS - This invention relates to a shear and temperature stable antibody formulations that are more stable than compared to a standard formulation (such as 30 mM citrate, 100 mM NaCl, pH 6.5). The present invention's shear and temperature stable antibody formulations show reduced precipitation when subjected to stress conditions but the standard formulation had aggregated. This result was unpredictable because thermodynamically the two formulations are similar as seen by their DSC (differential scanning calorimeter) profiles. | 2010-07-29 |
20100189722 | ANTI CD37 ANTIBODIES - Chimeric and humanized anti-CD37 antibodies and pharmaceutical compositions containing them are useful for the treatment of B cell malignancies and autoimmune and inflammatory diseases that involve B cells in their pathology. | 2010-07-29 |
20100189723 | ANTI-KIR ANTIBODIES, FORMULATIONS, AND USES THEREOF - A novel IgG4 isotype anti-KIR antibody, novel formulations of this and other IgG4 anti-KIR antibodies, and methods of using such formulations are provided. Also described are compositions, formulations, dosages, and administration regimens suitable for NK cell activation and therapeutic applications of anti-KIR antibodies, as well as kits comprising one or more anti-KIR antibodies with instructions for use in treating cancer. | 2010-07-29 |
20100189724 | METHOD FOR SCREENING OF PATIENT TO BE ADMINISTERED WITH PHARMACEUTICAL AGENT COMPRISING ANTI-CANCER ANTIBODY AS ACTIVE INGREDIENT - The present invention provides a method for screening a patient to be administered with a pharmaceutical composition which comprises an anti-cancer antibody as an active ingredient, said method comprising collecting samples from patients who expresses an antigen which is recognized by the anti-cancer antibody, measuring cadherin function in the samples, and selecting a patient whose the cadherin function is decreased or deleted; a method for screening a patient who has a high efficacy ratio for a pharmaceutical composition which comprises an anti-cancer antibody as an active ingredient; and a method for improving an efficacy ratio for a pharmaceutical composition which comprises an anti-cancer antibody as an active ingredient. | 2010-07-29 |
20100189725 | P53 MODULATOR AND CANCER TARGET - Methods of screening for modulators of TRIM24 (also known as TIF1-ALPHA) expression and/or biological activity are described. In particular, methods of screening of screening for modulators of TRIM24 E3 ligase activity, and specifically an E3 ligase activity directed at p53 as the target polypeptide are also described. Modulators of TRIM24 expression and activity are provided and their use in treatment of cancer, particularly in breast, colon, prostate, renal cancers and in acute lymphoblastic leukaemia. Suitable modulators of TRIM24 expression include siRNA and shRNA and can be used in the treatment of cancer and for targeting cancer stem cells. | 2010-07-29 |
20100189726 | LPAAT-BETA INHIBITORS AND USES THEREOF - The invention relates to triazines and the use thereof to inhibit lysophosphatidic acid acyltransferase β (LPAAT-β) activity. The invention further relates to methods of treating cancer using said triazines. The invention also relates to methods for screening for LPAAT-β activity. | 2010-07-29 |
20100189727 | Masking Ligands For Reversible Inhibition Of Multivalent Compounds - Masking ligands for reversibly concealing the antigen-binding site of an antibody comprise epitopes of the antibody and a cleavable linker. Methods for making masking ligands comprise joining at least two copies of the epitope of an antibody to a cleavable polypeptide linker. | 2010-07-29 |
20100189728 | Generation of Antigen Specific T Cells - The present invention is directed to a method of generating antigen specific T cells. Furthermore, the invention is directed to antigen specific T cells, isolated transgenic TCR's, pharmaceutical compositions containing same and their use in adoptive cell therapy. This invention in particular pertains to the use of cells co-expressing allogeneic MHC molecules and antigens to induce peptide-specific T cells from non-selected allogeneic T cell repertoires. | 2010-07-29 |
20100189729 | RNA-CODED ANTIBODY - The present application describes an antibody-coding, non-modified or modified RNA and the use thereof for expression of this antibody, for the preparation of a pharmaceutical composition, in particular a passive vaccine, for treatment of tumours and cancer diseases, cardiovascular diseases, infectious diseases, auto-immune diseases, virus diseases and monogenetic diseases, e.g. also in gene therapy. The present invention furthermore describes an in vitro transcription method, in vitro methods for expression of this antibody using the RNA according to the invention and an in vivo method. | 2010-07-29 |
20100189730 | VACCINES FOR HUMAN PAPILLOMA VIRUS AND METHODS FOR USING THE SAME - Improved anti-HPV immunogens and nucleic acid molecules that encode them are disclosed. Immunogens disclosed include those having consensus HPV 18 E6 and E7. Pharmaceutical composition, recombinant vaccines comprising and live attenuated vaccines are disclosed as well methods of inducing an immune response in an individual against HPV are disclosed. | 2010-07-29 |
20100189731 | RECOMBINANT AVIAN INFLUENZA VACCINE AND USES THEREOF - The present invention encompasses influenza vaccines, in particular avian influenza vaccines. The vaccine may be a subunit vaccine based on the hemagglutinin of influenza. The hemagglutinin may be expressed in plants including duckweed. The invention also encompasses recombinant vectors encoding and expressing influenza antigens, epitopes or immunogens which can be used to protect animals against influenza. It encompasses also a vaccination regimen compatible with the DIVA strategy, including a prime-boost scheme using vector and subunit vaccines. | 2010-07-29 |
20100189732 | CIRCOVIRUS SEQUENCES ASSOCIATED WITH PIGLET WEIGHT LOSS DISEASE (PWD) - The genome sequences and the nucleotide sequences coding for the PWD circovirus polypeptides, such as the circovirus structural and non-structural polypeptides, vectors including the sequences, and cells and animals transformed by the vectors are provided. Methods for detecting the nucleic acids or polypeptides, and kits for diagnosing infection by a PWD circovirus, also are provided. Method for selecting compounds capable of modulating the viral infection are further provided. Pharmaceutical, including vaccine, compositions for preventing and/or treating viral infections caused by PWD circovirus and the use of vectors for preventing and/or treating diseases also are provided. | 2010-07-29 |
20100189733 | CIRCOVIRUS SEQUENCES ASSOCIATED WITH PIGLET WEIGHT LOSS DISEASE (PWD) - The genome sequences and the nucleotide sequences coding for the PWD circovirus polypeptides, such as the circovirus structural and non-structural polypeptides, vectors including the sequences, and cells and animals transformed by the vectors are provided. Methods for detecting the nucleic acids or polypeptides, and kits for diagnosing infection by a PWD circovirus, also are provided. Method for selecting compounds capable of modulating the viral infection are further provided. Pharmaceutical, including vaccine, compositions for preventing and/or treating viral infections caused by PWD circovirus and the use of vectors for preventing and/or treating diseases also are provided. | 2010-07-29 |
20100189734 | CIRCOVIRUS SEQUENCES ASSOCIATED WITH PIGLET WEIGHT LOSS DISEASE (PWD) - The genome sequences and the nucleotide sequences coding for the PWD circovirus polypeptides, such as the circovirus structural and non-structural polypeptides, vectors including the sequences, and cells and animals transformed by the vectors are provided. Methods for detecting the nucleic acids or polypeptides, and kits for diagnosing infection by a PWD circovirus, also are provided. Method for selecting compounds capable of modulating the viral infection are further provided. Pharmaceutical, including vaccine, compositions for preventing and/or treating viral infections caused by PWD circovirus and the use of vectors for preventing and/or treating diseases also are provided. | 2010-07-29 |
20100189735 | CIRCOVIRUS SEQUENCES ASSOCIATED WITH PIGLET WEIGHT LOSS DISEASE (PWD) - The genome sequences and the nucleotide sequences coding for the PWD circovirus polypeptides, such as the circovirus structural and non-structural polypeptides, vectors including the sequences, and cells and animals transformed by the vectors are provided. Methods for detecting the nucleic acids or polypeptides, and kits for diagnosing infection by a PWD circovirus, also are provided. Method for selecting compounds capable of modulating the viral infection are further provided. Pharmaceutical, including vaccine, compositions for preventing and/or treating viral infections caused by PWD circovirus and the use of vectors for preventing and/or treating diseases also are provided. | 2010-07-29 |
20100189736 | CIRCOVIRUS SEQUENCES ASSOCIATED WITH PIGLET WEIGHT LOSS DISEASE (PWD) - The genome sequences and the nucleotide sequences coding for the PWD circovirus polypeptides, such as the circovirus structural and non-structural polypeptides, vectors including the sequences, and cells and animals transformed by the vectors are provided. Methods for detecting the nucleic acids or polypeptides, and kits for diagnosing infection by a PWD circovirus, also are provided. Method for selecting compounds capable of modulating the viral infection are further provided. Pharmaceutical, including vaccine, compositions for preventing and/or treating viral infections caused by PWD circovirus and the use of vectors for preventing and/or treating diseases also are provided. | 2010-07-29 |
20100189737 | Meningococcal vaccines including hemoglobin receptor - The meningococcal haemoglobin receptor, HmbR, is used as a vaccine antigen in combination with one or more further antigens e.g. in combination with a meningococcal outer membrane vesicle, with another purified meningococcal antigen (e.g. fHBP, 287, NadA, NspA, NhhA, App, Omp85, LOS), with a conjugated meningococcal capsular saccharide, etc. | 2010-07-29 |